Literature DB >> 12392901

Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia.

B-N Kim1, J-H Woo, M-N Kim, J Ryu, Y S Kim.   

Abstract

To identify the clinical implications of extended-spectrum beta-lactamase (ESBL) production, 162 cases of Klebsiella pneumoniae bacteraemia in 154 adults were analysed. Of these cases, 44 (27.2%) were ESBL-producing (ESBLKP). Common sources of ESBLKP bacteraemia included primary bacteraemia (34.1%) and biliary infection (29.5%). The placement of a biliary drainage catheter, nosocomial acquisition, and prior antibiotic therapy were independently associated with ESBL production in multivariate analysis. More cases of ESBLKP than non-ESBLKP received inappropriate antibiotic therapy before culture results were reported (54.5 vs. 3.4%; P = 0.001). In 19 cases of ESBLKP, no significant difference in mortality was observed between patients who received appropriate empiric antibiotic therapy and those who did not (26.3 vs. 20.8%; P = 0.67). The mean length of hospital stay after the onset of bacteraemia was longer in the cases of ESBLKP than in the cases of non-ESBLKP (39.6 vs. 23.9 days; P = 0.008). Directly related mortality was not significantly different between the cases of ESBLKP and the cases of non-ESBLKP (23.3 vs. 20.0%; P = 0.65). None of the patients with biliary infection due to ESBLKP died (0/12; P = 0.03). In conclusion, ESBL production was not significantly associated with death but it had a considerable impact on patients with K. pneumoniae bacteraemia. Copyright 2002 The Hospital Infection Society

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12392901     DOI: 10.1053/jhin.2002.1288

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  27 in total

Review 1.  Clinical and economic impact of common multidrug-resistant gram-negative bacilli.

Authors:  Christian G Giske; Dominique L Monnet; Otto Cars; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

2.  Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.

Authors:  Vicki L Collins; Dror Marchaim; Jason M Pogue; Judy Moshos; Suchitha Bheemreddy; Bharath Sunkara; Alex Shallal; Neelu Chugh; Sara Eiseler; Pragati Bhargava; Christopher Blunden; Paul R Lephart; Babar Irfan Memon; Kayoko Hayakawa; Odaliz Abreu-Lanfranco; Teena Chopra; L Silvia Munoz-Price; Yehuda Carmeli; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

3.  National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases.

Authors:  Dror Marchaim; Tamar Gottesman; Orna Schwartz; Maya Korem; Yasmin Maor; Galia Rahav; Rebekah Karplus; Tsipora Lazarovitch; Eyal Braun; Hana Sprecher; Tamar Lachish; Yonit Wiener-Well; Danny Alon; Michal Chowers; Pnina Ciobotaro; Rita Bardenstein; Alona Paz; Israel Potasman; Michael Giladi; Vered Schechner; Mitchell J Schwaber; Shiri Klarfeld-Lidji; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

4.  Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.

Authors:  Cheol-In Kang; Sung-Han Kim; Wan Beom Park; Ki-Deok Lee; Hong-Bin Kim; Eui-Chong Kim; Myoung-Don Oh; Kang-Won Choe
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

5.  Cefotaxime resistance and outcome of Klebsiella spp bloodstream infection.

Authors:  M Ortega; F Marco; A Soriano; M Almela; J A Martínez; J López; C Pitart; J Mensa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-21       Impact factor: 3.267

6.  Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae infection causing septic shock in cancer patients with chemotherapy-induced febrile neutropenia.

Authors:  Youn-Jung Kim; Sung Min Jung; Jihoon Kang; Seung Mok Ryoo; Chang Hwan Sohn; Dong-Woo Seo; Kyoung Soo Lim; Jin Won Huh; Sung-Han Kim; Won Young Kim
Journal:  Intern Emerg Med       Date:  2019-01-01       Impact factor: 3.397

7.  Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae.

Authors:  Vikas P Chaubey; Johann Dd Pitout; Bruce Dalton; Terry Ross; Deirdre L Church; Daniel B Gregson; Kevin B Laupland
Journal:  BMC Res Notes       Date:  2010-04-27

8.  Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea.

Authors:  B Kim; J Kim; M-R Seo; S-H Wie; Y K Cho; S-K Lim; J S Lee; K T Kwon; H Lee; H J Cheong; D W Park; S Y Ryu; M-H Chung; M Ki; H Pai
Journal:  Infection       Date:  2013-03-16       Impact factor: 3.553

9.  Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum β-lactamase-producing enterobacteriaceae on hospital admission.

Authors:  Steven W Johnson; Deverick J Anderson; D Byron May; Richard H Drew
Journal:  Infect Control Hosp Epidemiol       Date:  2013-02-14       Impact factor: 3.254

10.  Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case-control study.

Authors:  Kyoung-Ho Song; Jae Hyun Jeon; Wan Beom Park; Sang-Won Park; Hong Bin Kim; Myoung-don Oh; Hyo-Suk Lee; Nam Joong Kim; Kang Won Choe
Journal:  BMC Infect Dis       Date:  2009-04-12       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.